PROLOR Biotech To Present Preclinical Data On Its Long-Acting
Clotting Factor Vlla At 2012 ASH Annual Meeting
ATLANTA and NES-ZIONA,
Israel, Dec. 7, 2012 /PRNewswire/ -- PROLOR Biotech,
Inc. (NYSE MKT: PBTH), today announced that the company will
present preclinical data on its long-acting clotting Factor VIIa
(Factor Vlla-CTP) at the 54th Annual Meeting of the American
Society of Hematology (ASH). The data will be discussed by
Dr. Gili Hart, Director of
Pre-Clinical Affairs at PROLOR and head of the company's
long-acting clotting factors program, in an oral poster
presentation on December 8, 2012.
PROLOR's Factor VIIa-CTP is in advanced preclinical
development for the treatment of hemophilia.
Top-line results of the Factor Vlla-CTP studies have been
previously reported by PROLOR. The results show that when compared
to commercially available Factor VIIa, Factor VIIa-CTP in
hemophilic mice demonstrated a markedly enhanced pharmacokinetic
profile and increased exposure, as evidenced by a prolonged
hemostatic effect and improved recovery, which is a measure of
clotting activity. Compared to commercially available Factor
VIIa, Factor VIIa-CTP in hemophilic mice demonstrated superior
thrombin generation parameters, and it resulted in greater survival
of the subjects. In these studies, the specific activity of
Factor VIIa-CTP was comparable to commercial Factor VIIa. The
study data also show that administration of Factor Vlla-CTP by
subcutaneous injection resulted in improved bioavailability and
prolonged exposure compared to intravenous administration of Factor
Vlla-CTP.
PROLOR CEO Dr. Abraham Havron
commented, "The ASH Annual Meeting is the largest and most
prominent gathering of hematology experts in the world. In
preclinical studies our long-acting clotting factors have
demonstrated the potential to significantly improve both the
prophylactic and on-demand treatment of patients with hemophilia,
and we welcome the opportunity to share these promising data with
leading hematology researchers."
Dr. Hart will present PROLOR's poster, "Factor VIIa-CTP,a Novel
Long-Acting Coagulation Factor with Enhanced Long Term Haemostatic
Effect and Improved Pharmacokinetics and Pharmacodynamic Properties
Following IV Administration in Hemophilic Animal Models," on
December 8, 2012 at 5.30 pm EST. The 2012 ASH Annual Meeting is being
held December 8-11, 2012 in
Atlanta, Georgia. For more
information, visit www.hematology.org/Meetings/Annual-Meeting/.
ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage
biopharmaceutical company applying unique technologies, including
patented CTP technology and its long-acting reversible-pegylation
technology, primarily to develop longer-acting proprietary versions
of already approved therapeutic proteins that currently generate
billions of dollars in annual global sales. The CTP
technology is applicable to virtually all proteins. PROLOR is
developing a long-acting version of human growth hormone, which
successfully completed a Phase II clinical trial. It also is
developing long-acting versions of Factor VIIa and Factor IX for
hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for
diabetes and obesity, all of which are in preclinical
development. For more information, visit
www.prolor-biotech.com.
Safe Harbor Statement: This press release
contains forward-looking statements, which may be identified by
words such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "would", "intends,"
"estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of
current clinical studies and preclinical experiments and the
effectiveness of PROLOR's long-acting protein programs, which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Investors are
cautioned that forward-looking statements involve risks and
uncertainties that may affect PROLOR's business and prospects,
including the risks that PROLOR may not succeed in generating any
revenues or developing any commercial products, including any
long-acting versions of human growth hormone, erythropoietin,
interferon beta, GLP-1 and other products; that the long-acting
products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing
studies may not continue to show substantial or any activity; that
the actual dollar amount of any grants from Israel's Office of the Chief Scientist is
uncertain and is subject to policy changes of the Israeli
government, and that such grants may be insufficient to assist with
product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the CTP platform technology could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in PROLOR's filings with the Securities and Exchange
Commission. The forward-looking statements contained in this
press release speak only as of the date the statements were made,
and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.
PROLOR
CONTACT:
|
MEDIA
CONTACT:
|
Shai
Novik, President
|
Barbara
Lindheim
|
PROLOR
Biotech, Inc.
|
BLL
Partners, LLC
|
Tel: +1
866 644-7811
|
+1 212
584-2276
|
Email:
shai@prolor-biotech.com
|
blindheim@bllbiopartners.com
|
SOURCE PROLOR Biotech, Inc.